In oral solid dose manufacture, the first processing constraint introduced by pulverized buffalo horn concentrate is hygroscopicity and elastic recovery under compaction. The raw material is identified as Cornu Bubali concentrate in multi-ingredient veterinary antipyretic and hemostatic preparations, and its keratin-associated peptide content requires moisture control before tableting. The API fraction is commonly dry-blended with microcrystalline cellulose at 30–40 wt%, lactose monohydrate at 20–30 wt%, croscarmellose sodium at 2–4 wt%, and colloidal silicon dioxide at 0.5–1.0 wt% before lubrication with magnesium stearate at 0.5–1.0 wt%. Direct compression above 40 wt% produces capping and lamination on rotary tablet presses; batch records from pilot-scale runs using 9 mm round flat-faced beveled tooling show elastic recovery at ejection when peak compaction force exceeds 18 kN. Wet granulation is therefore specified at higher potencies. A binder solution of povidone K30 at 3–5 wt% in purified water is added to a wet mass endpoint of 18–22% loss on drying, followed by screening through an 18-mesh sieve and fluid-bed drying at inlet air temperature not exceeding 60 °C. Dried granules are lubricated with sodium stearyl fumarate at 1.0–2.0 wt% when the formulation is moisture-sensitive. Compression is run at main compression force between 8 kN and 18 kN; breaking force is maintained above 40 N as described in USP <1217>, friability is kept below 1.0% after 100 revolutions per USP <1216>, and disintegration is tested in water at 37 ± 1 °C with a limit of not more than 15 minutes per USP <701>. Dissolution is run under USP <711> Apparatus 2 at 50 rpm in 900 mL of pH 6.8 medium, with Q not less than 75% at 45 minutes. The finished tablet is packaged in cold-form aluminum foil because the concentrate is hygroscopic, and moisture is controlled to not more than 3.0% by USP <921>.

Aqueous injectable processing of pulverized buffalo horn concentrate begins with dissolution in Water for Injection at a concentration typically not exceeding 10% w/v because higher loads reduce filter throughput and promote precipitation at 2–8 °C. The bulk solution is adjusted to pH 5.5–7.0 with dilute hydrochloric acid or sodium hydroxide, then prefiltered through a 0.45 μm polyethersulfone membrane before final aseptic filtration through a 0.22 μm PVDF cartridge. Steam sterilization of the final solution is not the default route for heat-labile peptide fractions; preformulation thermostability screening at 60 °C, 80 °C, and 121 °C for 15 minutes determines whether terminal sterilization can be substituted for aseptic processing. Aseptic filling is performed under EU GMP Annex 1 Grade A conditions with a Grade B background; Grade A corresponds to ISO 14644-1 Class 5 airborne particulate limits. Bulk solution hold time is validated not to exceed 8 hours at 20–25 °C before filter integrity testing by the bubble point method according to the membrane manufacturer’s specification. For lyophilized injectables, mannitol is added at 2–5% w/v as a crystallizing bulking agent, and the solution is filled into 5 mL or 10 mL Type I borosilicate glass vials with chlorobutyl rubber stoppers. A representative lyophilization cycle ramps shelf temperature from −40 °C to +25 °C over 24–36 hours, with primary drying chamber pressure at 100–200 μbar; residual moisture in the cake is not more than 2.0% by USP <921> Karl Fischer titration. The reconstituted solution must meet USP <788> Method 1 limits of not more than 6000 particles ≥10 μm and not more than 600 particles ≥25 μm per container. Bacterial endotoxins are controlled per USP <85>; the acceptance criterion is derived from the maximum bolus dose in the target species, with 0.5 EU/mg commonly used for injectable veterinary APIs but requiring label-dose justification. Sterility testing follows USP <71> using membrane filtration with fluid thioglycollate medium and soybean-casein digest medium.

Because the milled horn concentrate exhibits bulk density values that frequently fall below 0.45 g/mL and an angle of repose above 40° at moisture content above 5.0%, hard-shell capsule filling requires dry granulation before encapsulation. The powder is processed through a roller compactor with nip angle set to 15–20° and specific compaction force between 6 kN/cm and 12 kN/cm, then milled through a 1.0 mm screen. The granulated fraction is blended with microcrystalline cellulose at 25–35 wt% and pregelatinized starch at 10–15 wt%. Capsule filling on a tamping pin machine is run with a target weight of 350 mg in size 0 hard capsules; fill weight variance is monitored under USP <905> criteria for content uniformity of veterinary actives. Sodium stearyl fumarate at 0.5–1.0 wt% is preferred over magnesium stearate when acidic-medium dissolution is marginal, because magnesium stearate can slow wetting of high-protein powders. The filled capsule must disintegrate within 30 minutes in water at 37 ± 1 °C per USP <701> and release not less than 75% at 45 minutes in 900 mL of 0.1 N hydrochloric acid under USP <711> Apparatus 2 at 50 rpm. Low-aldehyde gelatin or HPMC capsules are specified when accelerated stability at 40 °C/75% RH shows pellicle formation because residual amino acids in the horn concentrate can react with aldehyde impurities in conventional gelatin shells.

What Liquid Filling Parameters Prevent Phase Separation in Oral Drench Solutions?

Oral solutions and drench preparations are manufactured by dissolving the concentrate in purified water at 50–60 °C under high-shear mixing, then cooling to room temperature before preservative addition. The maximum stable concentration is established by phase-solubility testing; when the concentrate exceeds 15% w/v, settled solids typically appear within 24 hours at 4 °C, requiring a clarification step through a 1.0 μm polypropylene depth filter. A preservative system of sodium benzoate at 0.1% w/v and potassium sorbate at 0.1% w/v is used when the formulation pH is adjusted to 4.5–5.5, because benzoic acid requires an un-dissociated fraction to cross microbial membranes. For ruminant drench formulations, propylene glycol is added at 5–10% v/v to suppress freezing and act as a co-solvent for lipid-soluble peptide degradation products. The finished solution is filled into amber polyethylene terephthalate bottles with induction-sealed closures, and closure integrity is confirmed by dye penetration testing under vacuum per USP <1207>. Microbial enumeration tests follow USP <61> and USP <62>, with a total aerobic microbial count not exceeding 10³ CFU/mL and absence of Escherichia coli in 1 mL. Stability-indicating assay for soluble protein content is performed at release and at 6, 12, and 24 months under 25 °C/60% RH and 40 °C/75% RH. The operational boundary is that the formulation should not be combined with strong oxidizing agents or quaternary ammonium disinfectants in the same dosing line, because these can precipitate denatured keratin fragments and block the drench nozzle.

When Povidone Viscosity Falls Below 150 mPa·s, Granulation Endpoint Control Is Required

When a wet granulation step is selected for the final granule dosage form, the horn concentrate is preblended with lactose monohydrate and maize starch in a high-shear mixer-granulator. A 5% w/v povidone K30 solution in purified water is metered at a spray rate of 0.5–1.0 kg/min per 100 kg batch, with impeller speed at 150–200 rpm and chopper speed at 1500 rpm. The binder solution viscosity is controlled between 80 and 150 mPa·s; if viscosity falls below 150 mPa·s because of extended hold time, granule friability increases and endpoint control becomes unreliable. The wet mass endpoint is 18–22% moisture as measured by loss on drying. Wet granules are passed through an 8-mesh screen and dried in a fluid-bed dryer with inlet air at 55–65 °C until final moisture is not more than 3.0% by USP <921>. Dried granules are size-reduced through a 14-mesh sieve and tested by USP <1174> powder flow methods; Hausner ratio should be less than 1.25 and Carr’s compressibility index less than 20%. If Hausner ratio exceeds 1.35, the dried granule is re-screened and colloidal silicon dioxide at 0.5 wt% is added by tumbling blending for 10 minutes. Granules filled into stick packs are sealed in aluminum foil laminate with oxygen transmission below 0.1 cm³/m²/day to limit methionine oxidation in the concentrate. Dissolution is tested using USP <711> Apparatus 2 at 50 rpm in 900 mL of pH 6.8 phosphate buffer, with not less than 75% release at 45 minutes. The granulation formulation avoids amine-based binders such as shellac because residual free amines accelerate Maillard browning and reduce assay of lysine-derived peptides at 60 °C.

Medicated Premix Carryover Limits Under 21 CFR 225

Premix manufacture for feed mills uses the pulverized buffalo horn concentrate as a minor-active premix on a calcium carbonate or rice hull carrier. The concentrate is typically micronized so that not less than 95% passes through a 60-mesh screen to improve distribution in the final feed. A standard batch begins by blending the active concentrate with mineral oil at 0.5–1.5 wt% as a dust suppressant and with calcium carbonate q.s. to the desired inclusion rate in a ribbon mixer. Mix uniformity is determined by assay of 10 sampling points, with relative standard deviation not more than 5.0%. Production equipment is qualified for cleanout under FDA 21 CFR 225.30, and manufacturing follows current good manufacturing practice under FDA 21 CFR 225.1. Carryover into non-medicated feed is controlled by sequencing, flush batches, and validated cleanout; residue acceptance limits are derived from the labeled active concentration and target species safety margin, with a common default of not more than 1% of active drug carryover relative to the lowest approved medicated level. The premix is filled into multi-wall paper bags with a polyethylene inner liner, and labeling reconciliation follows FDA 21 CFR 225.65. Moisture is controlled to not more than 5.0% by USP <921> to prevent caking and microbial growth. Total aerobic plate count is limited to not more than 10⁵ CFU/g per USP <61> for non-sterile feed-grade raw materials.

Powder Sachet Fill Weight Variance at Low Bulk Density

For dry powder blends packaged for oral reconstitution, the low bulk density of the horn concentrate creates poor packing uniformity when filled by volumetric auger. The powder is dispersed by mixing with mannitol or sorbitol at 30–50 wt%, citric acid at 1–2 wt%, sodium bicarbonate at 1–2 wt% when effervescence is specified, and a palatability agent at levels below the veterinary acceptable daily intake. Pre-drying at 40 °C for 4 hours is required when ambient relative humidity exceeds 60% before sachet filling. Fill weight control on a sachet line is validated by gravimetric checkweighing every 15 minutes; for a target fill weight of 2,000 mg, the coefficient of variation should not exceed 2.0% across 10 consecutive sachets. The sachet material is a four-layer laminate of polyester, aluminum foil, and polyethylene with oxygen transmission below 0.1 cm³/m²/day and water vapor transmission below 0.1 g/m²/day. Powder blends are tested for bulk density and tapped density per USP <616>, and the Hausner ratio is maintained below 1.25. Reconstitution time in water at 25 °C is specified as not more than 60 seconds with magnetic stirring at 200 rpm. Because the horn concentrate contains high-molecular-weight keratin peptides, the reconstituted suspension is consumed within 24 hours; longer standing at room temperature produces microbial proliferation and sedimentation. Assay and content uniformity follow USP <905>, with acceptance value not more than 15 for single-dose powder sachets. Published data for this specific concentrate in oral reconstitutable powder is limited; therefore fill weight and reconstitution limits are established by development-scale design-of-experiments rather than a compendial monograph.